Skip to main content
. 2022 Mar 28;13(6):1933–1944. doi: 10.7150/jca.69338

Figure 2.

Figure 2

Effect of ONP-302 on immune-cell composition in the TME. LLC (A) tumor bearing C57BL/6 mice and MC-38 (B) tumor-bearing C57BL/6 mice were treated with vehicle or ONP-302 50mg/kg intravenously twice per week for 2 weeks. Single-cell suspensions were prepared from tumor and analyzed by flowcytometry. Percentages of T-cells (CD3+CD4+ or CD3+CD8+), NK cells (CD3- NK1.1+), TAM (CD11b+F4/80+), M-MDSC (CD11b+ Ly6Chi Ly6G-), and PMN-MDSC (CD11b+ Ly6C- Ly6G+) were measured.